Gladden Longevity Podcast -- formerly Living Beyond 120 Stem Cell Therapy Now – an Interview with Matthew Feshbach – Episode 26
Matthew Feshbach, founder and CEO of Ambrose Cell Therapy, joins the conversation to share information about stem cell research and treatment using stem cells. Feschbach explains the difference between types of stem cells and which are most effective for reparative therapies. They talk about why the body degenerates with age, related to stem cells.
Feshbach describes the process and technology his clinic uses to harvest mesenchymal stem cells for use in therapy. They consider some of the regulatory issues involved in stem cell therapy. Feshbach describes some of the amazing results that have been seen in patients who have received the therapy to treat significant health issues. He explains what sort of lifestyle choices can optimize results from this kind of treatment.
Also on the podcast, Mark and Dr. Gladden discuss the problem with staying in your comfort zone, both physically and mentally. In contrast, they describe the environments in which we grow and thrive.
Special Guest:
Matthew (Matt) Feshbach is the Founder and CEO of AMBROSE Cell Therapy. AMBROSE was founded in 2017 with the mission: To help people with chronic degenerative diseases improve symptoms, function and quality of life with adult stem cell therapy.
Matt has taken an unconventional path throughout his business career. He did not attend college but instead taught tennis at private homes in Silicon Valley. Through that experience he developed professional and personal relationships with a number of prominent investment managers, who inspired him to study securities analysis and begin investing himself.
This led to the co-founding, with his brothers Kurt and Joe, of Feshbach Bros in 1982. Feshbach Bros. managed the first "short-only" hedge fund. Assets under management grew from $20,000 to $1 Billon in 9 years. Matt's investment career, through the ups and downs of the stock market, spanned more than 30 years.
In 2009 he and his brother, Joe, began researching adult stem cells and their potential, due to their interest in a publicly traded company. They spoke to researchers from all over the world - Israel to Japan, Holland to Spain, New York to Los Angeles, Chicago to Dallas and so on - to understand the best source of adult stem cells as well as the science, technologies and unmet medical needs they could potentially address.
As a result of their research, they came to have a well-informed opinion that fat (adipose) tissue is the most accessible, abundant and potent source of adult stem and regenerative cells. As well, that the mixed population of adipose-derived stem and regenerative cells (ADRCs) could be used to address a broad spectrum of chronic diseases. This has now been validated in the published medical literature. 1 2 3
Along with his brother, Matt founded Okyanos (Oh-key-ah-nos) Cell Therapy in August 2011 in Freeport, Bahamas. The Greek God of Rivers, "Okyanos" symbolizes restoration of blood flow, which is an important mechanism of action of ADRCs. Shortly after helping to create Okyanos, Matt's brother, Joe, sadly died of a cardiac arrest. Joe's death prompted Matt to be even more dedicated his purpose to help patients with chronic disease with their own adult stem cells.
In the Bahamas, he drafted the framework for what developed into the Bahamas Stem Cell Research and Therapy Act, while concurrently building and staffing Okyanos. Due to the uncompromising standards set by Matt, Okyanos came to be known as the first cell therapy center of excellence in the world.
The passage of House Bill 810, Charlie's Law, in Texas paved the way for Matt to once again set a new standard in cell therapy for complex chronic disease. To be specific, Charlie's Law allows the use of investigational adult stem cell treatments in Texas for patients that have been diagnosed with a terminal illness or severe chronic disease. This is a Right-to-Try Law.
The U.S Constitution - Tenth Amendment states - "The powers not delegated to the United States by the Constitution, nor prohibited by it to the States, are reserved to the States
respectively, or to the people."
As such FDA has not taken action against drug companies or providers in the 28 states with medical marijuana laws and the 38 states with laws allowing patients who are terminally ill the right to try experimental drugs without FDA approval (Right to try Laws), respectively.
Matthew Feshbach has combined his 3 decades of investment experience with his personal
purpose to help others and, for a non-medical person, extraordinary knowledge of the science,
technology and protocols of adult stem cell therapy to bring the highest standards of safety, care and potential effectiveness to patients in need.
1 A Nguyen, A et al Stromal vascular fraction: A regenerative reality? Part 1: Current concepts and review of the literature Journal of Plastic, Reconstructive & Aesthetic Surgery (2016) 69, 170e179
2 Guo et al Stromal vascular fraction: A regenerative reality? Part 2: Current concepts and review of the literature Journal of Plastic, Reconstructive & Aesthetic Surgery (2016) 69, 180e188
3 JK Fraser PhD and S Kesten MD Autologous Adipose Derived Regenerative Cells: A platform for therapeutic applications Advanced Wound Healing Surgical Technology International XXIX
You can contact Feschbach via email or by phone:
(727) 743-1510